Vahan Kassabian, MD
Urology · Roswell, GANPI 1730283284
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,265,566 of the $1,646,316 with a category attached, or 76.9%. It is spread thinly across 60 manufacturers, the largest accounting for just 21.3%. Among urology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,850 payments — averaging $889.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$351K
- Astellas Pharma US Inc$248K
- Merck$221K
- Bayer$168K
- Dendreon Pharmaceuticals LLC$130K
- Urogen Pharma, Inc.$110K
- plus $418K from 54 others
Across 90 payments — averaging $15,513 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.3M
- Dendreon Pharmaceuticals LLC$87K
- AstraZeneca$8K
What the payments were for
- Consulting fees$116,4847%
- Speaking & faculty fees$1,265,56677%
- Travel & lodging$217,28513%
- Food & beverage$46,6333%
- Education$3470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,646,316 in reported general payments places this provider in the 95th percentile of 369 urology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 151 | $2,168,208 |
| XtandiEnzalutamide | 104 | $1,421,353 |
| OrgovyxRelugolix | 124 | $325,058 |
| NubeqaDarolutamide | 11 | $144,971 |
| Abiraterone Acetate | 57 | $94,612 |
| MyrbetriqMirabegron | 40 | $26,710 |
| Tamsulosin Hcl | 372 | $3,792 |
| Methenamine Hippurate | 31 | $2,285 |
| Oxybutynin Chloride ErOxybutynin Chloride | 105 | $1,650 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 71 | $1,163 |
| Testosterone | 14 | $1,134 |
| Testosterone Cypionate | 17 | $707 |
| Finasteride | 37 | $697 |
| Cefdinir | 35 | $505 |
| Prednisone | 64 | $293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $350,996 | $2,168,208151 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $248,036 | $1,448,063144 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $98,229 | $325,058124 claims |
| BayerNubeqa | $168,087 | $144,97111 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $7,698 | $94,61257 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 369 urology providers in Georgia.
Other urology in Roswell
- Lewis KritemanRoswell$864K
- Scott MillerRoswell$85K
- Akash KapadiaRoswell$63K
- Sophia GoodridgeRoswell$18K
- Daniel BelewRoswell$16K
- Rutveej PatelRoswell$15K
- Daniel CanterDecatur$329K
- Tariq HakkyAtlanta$140K
- Sherita KingAugusta$108K
- Brittani Barrett-HarlowFayetteville$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.